NEW YORK, Jan. 27, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SciClone Pharmaceuticals, Inc. ("SCLN" or the "Company") (NASDAQ: SCLN) Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 237.
The investigation concerns whether SCLN and certain of its officers and/or directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On January 24, 2014, the Company filed a Form 8-K with the Securities and Exchange Commission ("SEC"), identifying a number of internal control deficiencies with respect to the Company's revenue recognition and accounting for reserves.
On this news, shares of SCLN fell $0.13 per share, or more than 2.53% on intraday trading to a price of $5.01 on January 27, 2014.The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. CONTACT: Robert S. WilloughbyPomerantz LLP email@example.com SOURCE Pomerantz LLP